PRODUCT IDENTIFICATION
H.S. CODE
TOXICITY
CLASSIFICATION
PHYSICAL AND CHEMICAL PROPERTIES
REFRACTIVE INDEX
NFPA RATINGS
AUTOIGNITION
FLASH POINT
EXTERNAL LINKS & GENERAL DESCRIPTION
Soy isoflavones have effects in the body somewhat similar to those of estrogen. This should be beneficial, but it is possible that soy could present some of the risks of estrogen, as well. In 1969, a research project was initiated to manufacture a type of isoflavone that would possess the bone-stimulating effects of estrogen without any estrogen-like activity elsewhere in the body. Such a product would help prevent osteoporosis, but cause no other health risks. Ipriflavone was the result. After 7 successful years of experiments with animals, human research was started in 1981. Today, ipriflavone is available in over 22 countries and in most drugstores in the United States as a nonprescription dietary supplement. It is an accepted treatment for osteoporosis in Italy, Turkey, and Japan. (http://healthlibrary.epnet.com/)
Ipriflavone is a synthetic flavonoid (isoflavone) derived from the soy compound daidzein. Ipriflavone promotes the incorporation of calcium into bone. It also inhibits bone breakdown. Many clinical studies, including numerous double-blind studies, have clearly shown that long-term treatment with ipriflavone (along with 1,000 mg supplemental calcium per day) is both safe and effective in halting bone loss in postmenopausal women or in women who have had their ovaries removed. Ipriflavone has also been found to improve bone density in cases of osteoporosis.(http://www.mothernature.com/)Ipriflavone is a synthetic analogue of bio-isoflavone. It is believed to act like estrogen (a female steroid) in massing bones. It is used as a feed supplement to prevent prophylaxis of osteoporosis.
APPEARANCE
ASSAY
99.0% min
LOSS ON DRYING
1.0% max
HEAVY METALS
10ppm max
